FDA Clinical Investigator Oversight Weak On Recruitment Tactics, OIG Report
This article was originally published in The Gray Sheet
Executive Summary
Protocol violations by medical device clinical investigators were cited in 78% (83/107) of official actions by FDA's Center for Devices and Radiological Health between fiscal years 1994-99, the HHS Office of Inspector General states in a report on FDA oversight of clinical investigators released June 12.
You may also be interested in...
BIMO Would Step Up Inspections Of IRBs, Device Trial Sponsors In FY 2002
On-site inspections of the device research community through CDRH's Bioresearch Monitoring (BIMO) Program would increase by 30% to 325 annually, under President Bush's fiscal 2002 budget proposal.
BIMO Would Step Up Inspections Of IRBs, Device Trial Sponsors In FY 2002
On-site inspections of the device research community through CDRH's Bioresearch Monitoring (BIMO) Program would increase by 30% to 325 annually, under President Bush's fiscal 2002 budget proposal.
FDA Civil Monetary Penalties For Human Subject Protection Sought By HHS
HHS plans to submit a legislative proposal to Congress by year-end that would authorize FDA to levy civil monetary penalties for infractions of human research subject protections rules, the Clinton administration announced May 23.